z-logo
Premium
Ropivacaine in peribulbar block: a comparative study with bupivacaine
Author(s) -
Nociti J. R.,
Mateus Serzedo P. S.,
Zuccolotto E. B.,
Cagnolati C. A.,
Machado Nunes A. M.
Publication year - 1999
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1034/j.1399-6576.1999.430803.x
Subject(s) - ropivacaine , medicine , bupivacaine , anesthesia , local anesthetic , block (permutation group theory) , hyaluronidase , potency , surgery , biochemistry , chemistry , geometry , mathematics , in vitro , enzyme
Background: Ropivacaine is a new local anesthetic with alleged lower systemic toxicity and slightly lower potency as compared with bupivacaine. The present study aimed to evaluate the efficacy of ropivacaine in peribulbar block, as compared with that of bupivacaine. Methods: Eighty patients aged 45–92 years with physical status ASA I, II, or III were randomized to Group R (n=40) or Group B (n=40). Group R received 8.0 ml of 1.0% ropivacaine and Group B received 8.0 ml of 0.75% bupivacaine, both solutions with 50 IU/ml hyaluronidase, to induce peribulbar block according to the double‐injection technique. Decreased ocular motility was the only criterion of successful block. Results: The percentage of patients with decreased ocular motility showing successful block was higher in Group R 1 and 5 min after injection. A score indicating successful peribulbar block was found in all patients 10 min after injection. While no patient complained of a burning sensation during ropivacaine injection, 22.5% of the patients given bupivacaine reported this symptom. Conclusion: Both local anesthetics were effective in inducing peribulbar block for intraocular surgery. A tendency was noted to a faster onset of peribulbar block with ropivacaine; nevertheless, both drugs had a high degree of success for this block.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here